Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate

Synapse

Volumn 71, Issue 7, 2017, Pages

  Migdalska Richards, Anna ^a   Ko, Wai Kin D ^b   Li, Qin ^b,c   Bezard, Erwan ^b,c,d,e   Schapira, Anthony H V ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Williams House   (United Kingdom)

^c INSTITUTE OF LABORATORY ANIMAL SCIENCE   (China)

^d UNIVERSITÉ DE BORDEAUX   (France)

^e INSTITUT DES MALADIES NEURODÉGÉNÉRATIVES   (France)

Author keywords

ambroxol; glucocerebrosidase; nonhuman primate; Parkinson disease

Indexed keywords

ALPHA SYNUCLEIN; AMBROXOL; GLUCOSYLCERAMIDASE; BETA N ACETYLHEXOSAMINIDASE BETA CHAIN; CENTRAL NERVOUS SYSTEM AGENTS;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; ENZYME ACTIVITY; GENE OVEREXPRESSION; MACACA FASCICULARIS; MESENCEPHALON; MOUSE; NONHUMAN; PRIMATE; PRIORITY JOURNAL; WILD TYPE; ANIMAL; BRAIN; DRUG EFFECTS; ENZYMOLOGY; MALE; METABOLISM; ORAL DRUG ADMINISTRATION; PRELIMINARY DATA;

ADMINISTRATION, ORAL; AMBROXOL; ANIMALS; BETA-HEXOSAMINIDASE BETA CHAIN; BRAIN; CENTRAL NERVOUS SYSTEM AGENTS; GLUCOSYLCERAMIDASE; MACACA FASCICULARIS; MALE; PRELIMINARY DATA;

EID: 85016460436     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.21967     Document Type: Article

References (12)

1. Beutler, E. (1992). Gaucher disease: New molecular approaches to diagnosis and treatment. Science, 256, 794–799.
2. Bourdenx, M., Nilsson, A., Wadensten, H., Fälth, M., Li, Q., Crossman, A. R., …, Bezard, E. (2014). Abnormal structure-specific peptide transmission and processing in a primate model of Parkinson's disease and l-DOPA-induced dyskinesia. Neurobiology Disease, 62, 307–312.
3. Bultron, G., Kacena, K., Pearson, D., Boxer, M., Yang, R., Sathe, S., … Mistry, P. K. (2010). The risk of Parkinson's disease in type 1 Gaucher disease. Journal of Inherited Metabolic Disease, 33, 167–173.
4. Gegg, M. E., Burke, D., Heales, S. J., Cooper, J. M., Hardy, J., Wood, N. W., & Schapira, A. H. (2012). Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Annals of Neurology, 72, 455–463.
5. McNeill, A., Magalhaes, J., Shen, C., Chau, K. Y., Hughes, D., Mehta, A., … Schapira, A. H. (2014). Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain, 137, 1481–1495.
6. Migdalska-Richards, A., Daly, L., Bezard, E., & Schapira, A. H. (2016). Ambroxol effects in glucocerebrosidase and a-synuclein transgenic mice. Annals of Neurology, 80(5), 766–775.
7. Migdalska-Richards Schapira, A. H. (2016). The relationship between glucocerebrosidase mutations and Parkinson disease. Journal of Neurochemistry, 139, 77–90.
8. Murphy, K. E., & Halliday, G. M. (2014). Glucocerebrosidase deficits in sporadic Parkinson disease. Autophagy, 10(7), 1350–1351.
9. Santini, E., Sgambato-Faure, V., Li, Q., Savasta, M., Dovero, S., Fisone, G., & Bezard, E. (2010). Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in L-DOPA-induced dyskinesia. PLoS One, 235(8), e12322.
10. Schapira, A. H., & Gegg, M. E. (2013). Glucocerebrosidase in the pathogenesis and treatment of Parkinson disease. Proceedings of the National Academy of Sciences of the United States of America, 110, 3214–3215.
11. Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., … Ziegler, S. G. (2009). Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. The New England Journal of Medicine, 361, 1651–1661.
12. Wang, Q., Liu, Y., & Zhou, J. (2015). Neuroinflammation in Parkinson's disease and its potential as therapeutic target. Translational Neurodegeneration, 12, 4–19.